从COVID-19的发病机制到治疗

S. Yanev, G. Chaldakov
{"title":"从COVID-19的发病机制到治疗","authors":"S. Yanev, G. Chaldakov","doi":"10.14748/BMR.V31.7712","DOIUrl":null,"url":null,"abstract":"The world is facing the pandemic of a new coronavirus (SARS-CoV-2) leading to the development of coronavirus disease (COVID-19) In effect, the scientific potential in the field becoming the cutting-edge of biomedical research It is in a big race to test the available pharmacologic resource of registered antiviral drugs and to discover of novel pharmaceuticals, nutraceuticals and biologicals (such as vaccines, gene and stem cell therapy, and recombinant proteins produced biotechnologically) We argue that the knowledge of (i) angiotensin converting enzyme 2 (ACE2) receptor, (ii) viral S-glycoprotein ligand, and (iii) cellular proteases, required for the entry of Cov-2 into the target cell, may provide novel therapeutic approaches for COVID-19 Finally, we reason the described approaches could lead to the identification of better drugs for COVID-19 and post-COVID-19 syndrome","PeriodicalId":8906,"journal":{"name":"Biomedical Reviews","volume":"166 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"From pathogenesis to therapy of COVID-19\",\"authors\":\"S. Yanev, G. Chaldakov\",\"doi\":\"10.14748/BMR.V31.7712\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The world is facing the pandemic of a new coronavirus (SARS-CoV-2) leading to the development of coronavirus disease (COVID-19) In effect, the scientific potential in the field becoming the cutting-edge of biomedical research It is in a big race to test the available pharmacologic resource of registered antiviral drugs and to discover of novel pharmaceuticals, nutraceuticals and biologicals (such as vaccines, gene and stem cell therapy, and recombinant proteins produced biotechnologically) We argue that the knowledge of (i) angiotensin converting enzyme 2 (ACE2) receptor, (ii) viral S-glycoprotein ligand, and (iii) cellular proteases, required for the entry of Cov-2 into the target cell, may provide novel therapeutic approaches for COVID-19 Finally, we reason the described approaches could lead to the identification of better drugs for COVID-19 and post-COVID-19 syndrome\",\"PeriodicalId\":8906,\"journal\":{\"name\":\"Biomedical Reviews\",\"volume\":\"166 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14748/BMR.V31.7712\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14748/BMR.V31.7712","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

世界正面临着新型冠状病毒(SARS-CoV-2)的大流行,导致冠状病毒病(COVID-19)的发展。实际上,该领域的科学潜力成为生物医学研究的前沿。测试已注册抗病毒药物的可用药理学资源,发现新型药物、保健品和生物制品(如疫苗、基因和干细胞治疗)的竞赛正在进行。我们认为,了解(i)血管紧张素转换酶2 (ACE2)受体、(ii)病毒s -糖蛋白配体和(iii)细胞蛋白酶(Cov-2进入靶细胞所需)可能为COVID-19提供新的治疗方法。最后,我们认为所描述的方法可能导致鉴定出更好的药物用于COVID-19和COVID-19后综合征
本文章由计算机程序翻译,如有差异,请以英文原文为准。
From pathogenesis to therapy of COVID-19
The world is facing the pandemic of a new coronavirus (SARS-CoV-2) leading to the development of coronavirus disease (COVID-19) In effect, the scientific potential in the field becoming the cutting-edge of biomedical research It is in a big race to test the available pharmacologic resource of registered antiviral drugs and to discover of novel pharmaceuticals, nutraceuticals and biologicals (such as vaccines, gene and stem cell therapy, and recombinant proteins produced biotechnologically) We argue that the knowledge of (i) angiotensin converting enzyme 2 (ACE2) receptor, (ii) viral S-glycoprotein ligand, and (iii) cellular proteases, required for the entry of Cov-2 into the target cell, may provide novel therapeutic approaches for COVID-19 Finally, we reason the described approaches could lead to the identification of better drugs for COVID-19 and post-COVID-19 syndrome
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信